Engineered red blood cell extracellular vesicles for delivery of Dox and siIDO1 enhance targeted chemo-immunotherapy of acute myeloid leukemia
Background As a malignancy of hematopoietic origin, the standard-of-care cytoreductive chemotherapy can not provide satisfactory treatment effect for patients with acute myeloid leukemia (AML). Immunotherapy has received increasing attention in leukemia treatment. However, the immunosuppressive micr...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/7/e011148.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|